Daniel Savitt, DO
Neurology · Scottsdale, AZNPI 1992149603
Payments from drug & device makers
What this record shows
This record is dominated by grants: $6,250 of the $6,896 with a category attached, or 90.6%. Medtronic accounts for 93.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $6,650 and has fallen 99.7% since, to $21 in 2025.
Across 20 payments — averaging $344.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Boston Scientific$161
- Argenx US, Inc.$104
- Acorda Therapeutics, Inc$60
- Biogen$53
- AstraZeneca$32
- plus $61 from 4 others
Across 21 payments — averaging $2638.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$55K
What the payments were for
- Speaking & faculty fees$601%
- Grants$6,25091%
- Food & beverage$5858%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 5 | $6,426 |
| Boston Scientific | 2 | $161 |
| Argenx US, Inc. | 1 | $104 |
| Acorda Therapeutics, Inc | 3 | $60 |
| Biogen | 3 | $53 |
| AstraZeneca | 2 | $32 |
| MDD US Operations, LLC | 1 | $21 |
| Abbott | 1 | $14 |
| Merz North America, Inc. | 1 | $14 |
| Akcea Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA$6,250
- GENERAL DBS$135
- VYVGART$104
How this compares
$6,896 in reported general payments places this provider in the 65th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 107 | $706,400 |
| IngrezzaValbenazine Tosylate | 47 | $333,354 |
| RytaryCarbidopa/Levodopa | 112 | $165,030 |
| NuplazidPimavanserin Tartrate | 29 | $145,754 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 891 | $35,938 |
| NeuproRotigotine | 15 | $15,846 |
| Dalfampridine ErDalfampridine | 26 | $14,655 |
| Primidone | 256 | $10,942 |
| Entacapone | 60 | $10,939 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 179 | $7,797 |
| Propranolol Hcl | 251 | $6,624 |
| MyrbetriqMirabegron | 12 | $6,307 |
| Rasagiline Mesylate | 33 | $6,052 |
| Modafinil | 26 | $5,307 |
| Gabapentin | 234 | $5,234 |
Paid to pharmacies, not to this prescriber.
Other neurology in Scottsdale
- Nida LaurinScottsdale$969K
- Dean WingerchukScottsdale$324K
- Amaal StarlingScottsdale$315K
- Virgilio Gerald EvidenteScottsdale$231K
- Brent GoodmanScottsdale$198K
- David SapersteinScottsdale$135K
- Maciej MrugalaScottsdale$97K
- Charles AdlerScottsdale$74K
- Jill RauScottsdale$59K
- Shyamal MehtaScottsdale$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.